Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.

Deleu S, Kakuda TN, Spittaels K, Vercauteren JJ, Hillewaert V, Lwin A, Leopold L, Hoetelmans RMW.

Br J Clin Pharmacol. 2018 Nov;84(11):2663-2672. doi: 10.1111/bcp.13733. Epub 2018 Sep 14.

2.

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.

Kakuda TN, Brochot A, Green B, Nijs S, Vis P, Opsomer M, Tomaka FL, Hoetelmans RM.

J Clin Pharmacol. 2016 Nov;56(11):1395-1405. doi: 10.1002/jcph.746.

PMID:
27060341
3.

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.

Kakuda TN, Leopold L, Nijs S, Vandevoorde A, Crauwels HM, Bertelsen KM, Stevens M, Witek J, van Delft Y, Tomaka F, Hoetelmans RM.

J Clin Pharmacol. 2014 May;54(5):563-73. doi: 10.1002/jcph.245.

PMID:
25975423
4.

Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.

Kakuda TN, Sekar V, Lavreys L, De Paepe E, Stevens T, Vanstockem M, Vangeneugden T, Hoetelmans RM.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):346-52. doi: 10.1002/cpdd.88. Epub 2014 Feb 10.

PMID:
27129006
5.

Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.

Kakuda TN, Leopold L, Timmers M, Van De Casteele T, Hillewaert V, Tomaka FL, Hoetelmans RM.

Int J Clin Pharmacol Ther. 2014 Sep;52(9):805-16.

PMID:
25109510
6.

Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.

Kakuda TN, Van De Casteele T, Petrovic R, Neujens M, Salih H, Opsomer M, Hoetelmans RM.

Antivir Ther. 2014;19(6):597-606. doi: 10.3851/IMP2814. Epub 2014 Jun 25.

PMID:
24964392
7.

Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.

Kakuda TN, Brochot A, Tomaka FL, Vangeneugden T, Van De Casteele T, Hoetelmans RM.

J Antimicrob Chemother. 2014 Oct;69(10):2591-605. doi: 10.1093/jac/dku193. Epub 2014 Jun 20. Review.

PMID:
24951533
8.

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

van Heeswijk RP, Dannemann B, Hoetelmans RM.

J Antimicrob Chemother. 2014 Sep;69(9):2310-8. doi: 10.1093/jac/dku171. Epub 2014 May 23. Review.

PMID:
24860154
9.

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.

Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T, Hillewaert V, Petrovic R, Hoetelmans RM.

J Clin Pharmacol. 2014 Aug;54(8):949-57. doi: 10.1002/jcph.290. Epub 2014 Mar 26.

PMID:
24644095
10.

The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.

Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM.

J Clin Pharmacol. 2014 Feb;54(2):133-40. doi: 10.1002/jcph.222. Epub 2013 Nov 23.

PMID:
24203510
11.

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.

Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, Stevens T, Aharchi F, De Smedt G, Peeters M, Leopold L, Hoetelmans RM.

J Clin Pharmacol. 2014 Apr;54(4):422-31. doi: 10.1002/jcph.214. Epub 2013 Nov 19.

PMID:
24165884
12.

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Hoetelmans RM.

Int J Clin Pharmacol Ther. 2014 Feb;52(2):118-28. doi: 10.5414/CP201943.

PMID:
24161160
13.

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM.

J Antimicrob Chemother. 2014 Mar;69(3):728-34. doi: 10.1093/jac/dkt421. Epub 2013 Oct 23.

PMID:
24155058
14.

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies.

Hoetelmans RM, Dierynck I, Smyej I, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):299-305. doi: 10.1097/QAI.0000000000000011.

PMID:
24121757
15.

Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients.

Stellbrink HJ, Arastéh K, Schürmann D, Stephan C, Dierynck I, Smyej I, Hoetelmans RM, Truyers C, Meyvisch P, Jacquemyn B, Mariën K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):283-9. doi: 10.1097/QAI.0000000000000003.

PMID:
24121756
16.

Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.

Kakuda TN, Berckmans C, De Smedt G, Leemans R, Leopold L, Peeters M, Nijs S, Vyncke V, van Solingen-Ristea R, Hoetelmans RM.

Int J Clin Pharmacol Ther. 2013 Sep;51(9):725-37. doi: 10.5414/CP201770.

PMID:
23924679
17.

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM.

J Clin Pharmacol. 2013 Aug;53(8):834-40. doi: 10.1002/jcph.107. Epub 2013 May 30.

PMID:
23720136
18.

Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.

Schöller-Gyüre M, Kakuda TN, Witek J, Akuma SH, De Smedt G, Spittaels K, Vyncke V, Hoetelmans RM.

J Clin Pharmacol. 2013 Feb;53(2):202-10. doi: 10.1177/0091270012445205. Epub 2013 Jan 24.

PMID:
23436265
19.

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.

Kakuda TN, Van Solingen-Ristea R, Aharchi F, Smedt GD, Witek J, Nijs S, Vyncke V, Hoetelmans RM.

J Clin Pharmacol. 2013 Jan;53(1):41-50. doi: 10.1177/0091270011433329. Epub 2013 Jan 24.

PMID:
23400742
20.

Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.

Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM.

Antimicrob Agents Chemother. 2011 May;55(5):2290-6. doi: 10.1128/AAC.01046-10. Epub 2011 Mar 7.

21.

Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM.

Clin Pharmacokinet. 2011 Jan;50(1):25-39. doi: 10.2165/11534740-000000000-00000. Review.

PMID:
21142266
22.

Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM.

Clin Pharmacol Ther. 2010 Nov;88(5):695-703. doi: 10.1038/clpt.2010.181. Epub 2010 Sep 29.

PMID:
20881958
23.

Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM.

Antivir Ther. 2010;15(6):817-29. doi: 10.3851/IMP1652. Review.

PMID:
20834094
24.

Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.

Sekar V, Spinosa-Guzman S, De Paepe E, Stevens T, Tomaka F, De Pauw M, Hoetelmans RM.

Clin Pharmacokinet. 2010 May;49(5):343-50. doi: 10.2165/11530690-000000000-00000.

PMID:
20384396
25.

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

Schöller-Gyüre M, Kakuda TN, De Smedt G, Woodfall B, Berckmans C, Peeters M, Hoetelmans RM.

Clin Ther. 2010 Feb;32(2):328-37. doi: 10.1016/j.clinthera.2010.02.013.

PMID:
20206790
26.

Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.

Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM.

Intervirology. 2010;53(3):176-82. doi: 10.1159/000289341. Epub 2010 Mar 3.

27.

Clinical pharmacokinetics and pharmacodynamics of etravirine.

Schöller-Gyüre M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM.

Clin Pharmacokinet. 2009;48(9):561-74. doi: 10.2165/10895940-000000000-00000. Review.

PMID:
19725591
28.

Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

Sekar V, Lefebvre E, Mariën K, De Pauw M, Vangeneugden T, Pozniak A, Hoetelmans RM.

Br J Clin Pharmacol. 2009 Jul;68(1):116-9. doi: 10.1111/j.1365-2125.2009.03430.x.

29.

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.

Schöller-Gyüre M, Kakuda TN, Woodfall B, Aharchi F, Peeters M, Vandermeulen K, Hoetelmans RM.

Contraception. 2009 Jul;80(1):44-52. doi: 10.1016/j.contraception.2009.01.009. Epub 2009 Mar 17.

PMID:
19501215
30.

Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.

Kakuda TN, Schöller-Gyüre M, De Smedt G, Beets G, Aharchi F, Peeters MP, Vandermeulen K, Woodfall BJ, Hoetelmans RM.

HIV Med. 2009 Mar;10(3):173-81. doi: 10.1111/j.1468-1293.2008.00668.x. Epub 2009 Jan 7.

31.

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.

Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6.

32.

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.

Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RM.

Pharmacotherapy. 2008 Oct;28(10):1215-22. doi: 10.1592/phco.28.10.1215.

PMID:
18823217
33.

Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

Kakuda TN, Schöller-Gyüre M, Workman C, Arasteh K, Pozniak AL, De Smedt G, Beets G, Peeters M, Vandermeulen K, Woodfall BJ, Hoetelmans RM.

Antivir Ther. 2008;13(5):655-61.

PMID:
18771049
34.

Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.

Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, Hoetelmans RM.

Antivir Ther. 2008;13(4):563-9.

PMID:
18672535
35.

Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM.

Clin Drug Investig. 2008;28(8):479-85.

PMID:
18598093
36.

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

Schöller-Gyüre M, Kakuda TN, De Smedt G, Vanaken H, Bouche MP, Peeters M, Woodfall B, Hoetelmans RM.

Br J Clin Pharmacol. 2008 Oct;66(4):508-16. doi: 10.1111/j.1365-2125.2008.03214.x. Epub 2008 Apr 25.

37.

Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.

Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM.

Br J Clin Pharmacol. 2008 Aug;66(2):215-21. doi: 10.1111/j.1365-2125.2008.03191.x. Epub 2008 Apr 8.

38.

Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.

Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G.

Ann Pharmacother. 2008 Jun;42(6):757-65. doi: 10.1345/aph.1K681. Epub 2008 Apr 29.

PMID:
18445705
39.

Darunavir: pharmacokinetics and drug interactions.

Back D, Sekar V, Hoetelmans RM.

Antivir Ther. 2008;13(1):1-13. Review.

PMID:
18389894
40.

Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.

Schöller-Gyüre M, van den Brink W, Kakuda TN, Woodfall B, De Smedt G, Vanaken H, Stevens T, Peeters M, Vandermeulen K, Hoetelmans RM.

J Clin Pharmacol. 2008 Mar;48(3):322-9. doi: 10.1177/0091270007310387. Epub 2008 Jan 14.

PMID:
18195053
41.

Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.

Sekar VJ, Spinosa-Guzman S, De Paepe E, De Pauw M, Vangeneugden T, Lefebvre E, Hoetelmans RM.

J Clin Pharmacol. 2008 Jan;48(1):60-5.

PMID:
18094220
42.

Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.

Sekar VJ, Lefebvre E, Mariën K, De Pauw M, Vangeneugden T, Hoetelmans RM.

Ther Drug Monit. 2007 Dec;29(6):795-801.

PMID:
18043478
43.

Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.

Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E, Peeters M, Hoetelmans RM.

Antivir Ther. 2007;12(5):789-96.

PMID:
17713162
44.

Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.

Sekar VJ, De Pauw M, Mariën K, Peeters M, Lefebvre E, Hoetelmans RM.

Antivir Ther. 2007;12(4):509-14.

PMID:
17668559
45.

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

Hoetelmans RM, Mariën K, De Pauw M, Hill A, Peeters M, Sekar V, De Doncker P, Woodfall B, Lefebvre E.

Br J Clin Pharmacol. 2007 Nov;64(5):655-61. Epub 2007 Jul 4.

46.

Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.

Sekar VJ, Lefebvre E, De Marez T, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM.

Drugs R D. 2007;8(4):241-8.

PMID:
17596110
47.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

TMC125-C223 Writing Group, Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.

AIDS. 2007 Mar 30;21(6):F1-10.

PMID:
17413684
48.

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

Sekar V, Kestens D, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Lefebvre E, Hoetelmans RM.

J Clin Pharmacol. 2007 Apr;47(4):479-84.

PMID:
17389557
49.

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.

Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RM.

Antimicrob Agents Chemother. 2007 Mar;51(3):958-61. Epub 2007 Jan 8.

50.

Antiretroviral drug level monitoring: the next routine test in HIV management?

Hoetelmans RM.

Curr Opin Infect Dis. 1999 Dec;12(6):593-5.

PMID:
17035826

Supplemental Content

Loading ...
Support Center